Antares Pharma Inc.
250 Phillips Boulevard
Suite 290
Ewing,
NJ 08618
United States - Map
Phone: 609-359-3020
Fax: 609-359-3015
Web Site: http://www.antarespharma.com
| Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company. Its drug delivery platforms include Advanced Transdermal Delivery gels, disposable pressure assisted auto injection systems, reusable needle-free injection systems, disposable pen injection systems, and oral disintegrating tablets. The companys transdermal systems consist of semisolid dosage forms, which deliver medication and minimize gastrointestinal impact, as well as the initial liver metabolism effect of orally ingested drugs. Its injection device platform offers reusable needle-free injectors, which deliver precise medication doses through pressurized liquid penetration of the skin without a needle; disposable pressure assisted auto injectors that provide subcutaneous injections with minimal discomfort and safety of a shielded needle; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. In addition, the companys oral disintegrating tablets are designed to help patients experiencing difficulty in swallowing pills, tablets, or capsules. Antares Pharma sells its products through pharmaceutical and medical device companies primarily in the United States and Europe. It has collaborative arrangements and license agreements with BioSante Pharmaceuticals, Inc.; Jazz Pharmaceuticals; Population Council; Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; Eli Lilly and Company; JCR Pharmaceuticals Co., Ltd.; and Solvay Pharmaceuticals BV. The company was formerly known as Medi-Ject Corporation and changed its name to Antares Pharma, Inc. in January 2001. Antares Pharma, Inc. was founded in 1979 and is headquartered in Ewing, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul K. Wotton Ph.D., 48
Chief Exec. Officer, Pres |
$
247.00K | N/A | Mr. Robert F. Apple , 42
Exec. VP and Pres - Parenteral Products Division |
$
330.00K | N/A | Dr. Dario Carrara Ph.D., 45
Sr. VP and Managing Director of Pharmaceutical Group |
N/A
| N/A | Dr. Peter Sadowski Ph.D., 61
Sr. VP of the Parenteral Products Division |
N/A
| N/A | Dr. Kaushik J. Dave PhD, R.Ph., MBA.,
Sr. VP of Product Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
